Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C5MT
|
|||
| Drug Name |
Rintatolimod
|
|||
| Synonyms |
Ampligen
Click to Show/Hide
|
|||
| Drug Type |
Protein/peptide drug
|
|||
| Indication | Chronic fatigue syndrome [ICD-11: 8E49; ICD-10: G93.3] | phase 3 | [1] | |
| Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 1/2 | [2] | ||
| Therapeutic Class |
Antiviral Agents
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN toll-like receptor 3 (TLR3) | Target Info | Agonist | [3], [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00215813) Ampligen in Chronic Fatigue Syndrome. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04379518) Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients. U.S. National Institutes of Health. | |||
| REF 3 | Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Expert Rev Clin Pharmacol. 2016 Jun;9(6):755-70. | |||
| REF 4 | AIM ImmunoTech Announces FDA Authorization for First Human Ampligen Trial in COVID-19 Patients with Cancer; Provides Corporate Business Update for the First Quarter of 2020 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.